Cytomed Therapeutics six-month loss narrows to S$1.79 million; revenue rises to S$157,289

• Cytomed Therapeutics posted a loss for the six months ended June 30, 2026 of S$1.79 million, narrowing from S$2.25 million.
• Loss per share improved to S$0.15 from S$0.19, while revenue rose to S$157,289 from S$155,887.
• Other operating income fell to S$254,719 from S$385,779, while other losses/gains swung to a gain of S$10,263 from a loss of S$272,848.
• Cash and bank balances declined to S$1.46 million at June 30, 2026 from S$2.10 million at Dec. 31, 2025.
• The group reported net cash used in operating activities of S$1.65 million, compared with S$1.60 million a year earlier.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cytomed Therapeutics Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-045045), on September 30, 2026, and is solely responsible for the information contained therein.